RE:Conditions are right for biopharma M&A to break out" Raghav Mittal, assistant director at research firm Acuity Knowledge Partners, said in an email that acquisitions of biotech companies working on oncology or immunology treatments could be worth $5 billion to $25 billion a pop."
Well it appears that biotech analysts now view Big Pharm's M&A "sweet spot" as expanding to US$25 Billion.
Consequently ONCY'S acquisition value at US$10 Billion to US$15 Billion has become a very real proposition.